Novartis Foundation Symposium no. 223: Insect-Plant Interactions (Novartis Foundation Symposia)
How Appealing (Free subscription) | 44 minutes ago
"Microsoft Battles Novartis in High Court Patent Limits Dispute": Greg Stohr of Bloomberg News has a report that begins, " The U.S. Supreme Court today considers a patent dispute that will determine how much legal protection is afforded abstract business...
SeekingAlpha.com (Free subscription) | yesterday
The Burrill Report submits: The Swiss pharmaceutical giant Novartis ( NVS ) said it will invest $1 billion in China over the next five years including a significant expansion of the company’s biomedical research institute in Shanghai. On the heels of the announcement, the company also said it agreed to acquire an 85 percent stake in the Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical...
Market Watch (Free subscription) | 6 hours ago
MADRID (MarketWatch) -- U.K. pharmaceutical giant AstraZeneca was downgraded to underweight from neutral on Monday at JP Morgan, which said the company has a strong track record of beating estimates, but this will get tougher in coming quarters as it has to digest generic competition of high-margin products. JP Morgan expects three years of flat earnings from 2009 to 2012, and even a best-case scenario...
Indian Express (Free subscription) | 11 hours ago
If generics are the gateway of growth for global pharmaceutical giants such as AstraZeneca, Pfizer, Sanofi-Aventis, Novartis, Merck and GlaxoSmithKline, there is a clear and renewed thrust on the $17 billion Indian pharmaceutical market.
SeekingAlpha.com (Free subscription) | yesterday
ChinaBio Today submits: China life science news last week was dominated by stories of substantial foreign investments in China’s pharmaceutical sector. The Swiss biopharma Novartis ( NVS ) led the way, with nearly $1.4 billion in capital commitments to three separate initiatives in China. The company clearly feels that China represents growth – and Novartis has added significantly to its...
iStockAnalyst.com (Free subscription) | yesterday
Novartis made a five-year, $1 billion China commitment, building up its Shanghai R&D center and marketing efforts; Novartis will also spend $250 million to expand its global technical center in Changshu, and pay $125 million to buy a 85% stake in vaccine maker Zhejiang Tianyuan; Roche opened a new $500 million biologics manufacturing facility in Singapore; Microbix and Hunan Biopharmaceutical Co....
Thrive (Free subscription) | 07/11/2009
Other stories we’ve been reading: The Swiss drug maker, Novartis, says it will meet the United State’s H1N1 vaccine order on time and new research shows that people on cholesterol-lowering drugs are twice as likely to survive seasonal flu hospitalizations. The World Health Organization announced, again, that the H1N1 vaccine is safe and that one dose [...] Related posts: H1N1 (swine flu)...
Medical News Today (Free subscription) | 07/11/2009
Novartis announced that it received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A(H1N1) 2009 monovalent vaccine, Celtura®. Novartis continues to pursue registration in other major countries, including Japan and Switzerland.
Chemical and Engineering News (Free subscription) | 06/11/2009
Novartis makes major R&D and vaccines investments in China.
Just In Just Out (Free subscription) | 06/11/2009
Confederation of Indian Industry and U.S.-India Business Council Announce Healthcare Partnership The Confederation of Indian Industry and the U.S.-India Business Council today announced a major new advance in healthcare collaboration, partnering under the banner of the USIBC-led “Coalition for Healthy India”. The partnership was announced on the sidelines of CII’s 6 th Annual Healthcare...
Medical News Today (Free subscription) | 06/11/2009
The Wall Street Journal examines "big pharma's growing interest in a corner of healthcare - emerging-market inoculations," in light of a recent move by Novartis to purchase an 85 percent stake in the Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical Co.
Financial Times (Free subscription) | 06/11/2009
Prosecutors have raided the Seoul office of Roche on suspicions the Swiss drugs group illegally provided Tamiflu to HSBC and Novartis amid fears of a widespread...
SeekingAlpha.com (Free subscription) | 05/11/2009
Zacks.com submits: Human Genome Sciences, Inc. ( HGSI ) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or 50 cents in the year ago quarter. The lower net loss for the quarter was primarily attributable to increased revenues from manufacturing and development services and lower operating...
dBTechno (Free subscription) | 05/11/2009
Boston (DbTechNo) - A swine flu vaccine developed by Novartis has been approved by the German government for use across the country. The vaccine goes by the name Celtura, and is approved to vaccinate humans older than 6 months of age. The vaccine was developed by using dog kidney cells, opposed to the traditional method of growing [...]
Law Blog - WSJ.com (Free subscription) | 05/11/2009
The Swiss drug maker said it received regulatory approval in Germany to sell a new swine-flu vaccine made in cell cultures, marking an important milestone in gaining acceptance for newer, rapid ways of producing vaccines.
Videos